Sensai
Reading the tape…Pulling live market data…Setting the scene…
Sensai
AI Stock Dissection
AI Stock Dissection
ADVENZYMES
Thane, India · 409 employees
₹310.80
▬-0.02%Advenzymes' fundamentals hold firm as it gains on 21.6% YoY revenue growth and a modest 20.65 P/E, amidst an 18.64% institutional ownership.
Exchange
NSI
Currency
INR
Day range
₹305.80 – ₹320.00
52-week range
₹251.95 – ₹419.00
Sector
Basic Materials
Industry
Specialty Chemicals
AI investment rating
AI analysis60% confidence
Trading at the lower end of its 1-year range suggests Advenzymes may be slightly undervalued, yet this view remains tentative due to volatile market activity.
25.8% below the 1-year high · trend down
Hedge-fund memo
Today
-0.02% decline despite solid fundamentals and a stable 20.65 P/E
This week
Underperformed both the sector (0.15%) and the NIFTY 50 (-1.23%) within the 305.8–320 day range
This month
Outperforming the sector with a 4.25% return, compared to a 3.14% loss for the NIFTY 50
Bull thesis
Bear thesis
Hidden risks
Narrative read
Neutral
Composite sentiment
Institutional
Neutral
Retail
Neutral
News flow
Neutral
Read
Advenzymes remains a moderate focus within portfolios
Live news feed unavailable right now — showing the AI's qualitative read instead. Not scraped platform data.
Smart money
Named holders aren't published for this listing (common for Indian stocks). The split at left is live.
Financial health
Profitability
Growth
Balance sheet
Financial statements
Earnings intelligence
Earnings history unavailable for this symbol.
Competitive landscape
| Company | Market cap | P/E | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| ADVENZYMES | 34.80B | 20.65 | 11.02% | 26.33% | 21.60% |
| SUDARSCHEM | 82.06B | 369.46 | 1.03% | 5.46% | 106.50% |
| THYROCARE | 92.31B | 52.68 |
Technical intelligence
Volume
RSI (14) · 70 overbought / 30 oversold
MACD (12,26,9) · MACD vs signal
Candlesticks, volume, RSI and MACD from 500sessions of real Yahoo daily data. Moving averages use full history, so they're accurate at the left edge. Support / resistance are the 52-week low / high. Educational — technical signals are not buy or sell calls.
Risk intelligence
Regulatory changes affecting the enzymes industry
Mitigation: Diversified product and customer mix; focus on compliance with evolving regulations
Business intelligence
Competitive moat
Strong IP protection for its proprietary enzymes provides a durable competitive advantage.
Supply chain
Upstream (inputs / suppliers)
↓
Downstream (customers / markets)
M&A / strategic moves
Catalyst calendar
Update on financials and product diversification
Thesis builder
Bull case
Advenzymes' stable margins and a strong balance sheet enable a long-term market-beating strategy.
Base case
Its stable financials and moderate growth prospects justify a mid-single-digit return.
Bear case
Dependence on specific industries and limited geography could result in lower-than-expected returns.
Time horizon
2-3 years
Est. CAGR
10-12%
Entry (qual.)
Look for dips to the lower end of the 1-year range (around 285 INR) for a more attractive entry point.
Exit (qual.)
Consider selling at a 25% gain above the current price, or around 388 INR.
Overall conviction 60%
Knowledge graph
Executives & sector are live; peers are clickable → their dissection. Institutional holders shown where the exchange publishes them.
Portfolio impact
Enter tickers + weights, then see how ADVENZYMES fits.
Scenario simulator
Simulate a macro shock and see the illustrative impact:
Tailwind for tech & enablers.
Illustrative impact
Medium prob.Directional illustration only — not modelled on this company's actuals. A real simulator needs company financials.
Explain like…
Re-explain ADVENZYMES for a different audience:
Pick a persona to get a tailored explanation.
Sensai publishes educational market commentary, not investment advice. We are not SEBI-registered investment advisers or research analysts, and nothing here is a recommendation to buy, sell, or hold any security.
Live prices, index levels, and other market data are pulled from third-party feeds, may be delayed, and can be inaccurate or unavailable. Do not rely on them for trading decisions.
Investing in equities carries risk, including the loss of principal. Always do your own research and consider consulting a SEBI-registered adviser before making any investment decision.
Hidden opportunities
Watch next
Focus on core competencies while seeking incremental growth through strategic partnerships.
Annual income statement, oldest → newest. Live via Yahoo.
| — |
| 26.99% |
| 24.30% |
| ERIS | 197.68B | 31.56 | 18.07% | 27.12% | 7.10% |
Peers via Yahoo's similarity graph, same-sector first; fundamentals live. Ask the AI copilot below for a qualitative head-to-head.
Support (day/52w low)
₹305.80
Resistance (day/52w high)
₹320.00
Volume
1,60,850
Trend
down
RSI (14)
36
MACD
bullish
MA cross
golden
50-day MA
₹349.09
200-day MA
₹315.72
vs 200-DMA
-1.6%
RSI/MACD computed from 6 months of daily closes; moving averages from Yahoo. Options positioning still needs an options feed.